

# LAMPIRAN

## Lampiran 1. Izin Penelitian di Laboratorium



Nomor : 0266/UPT-lab/26.06.2022  
 Lamp. : -  
 Hal : Ijin Penelitian di Laboratorium

Kepada Yth. Bapak,Ibu Laboran dan PU

Di Tempat

Dengan hormat,

Sehubungan dengan penyelesaian penelitian mahasiswa, maka kami UPT laboratorium menyetujui untuk praktikum kepada :

Nama/NIM : Erry Pramudya/11180748N  
 Fakultas : Ilmu Kesehatan  
 Nomor Lab & Masa Berlaku : 2 selama 29 hari (tgl 27 juni – 29 Juli 2022)  
 Nomor Lab & Masa Berlaku : 13 selama 29 hari (tgl 27 juni – 29 Juli 2022)

\*Note : jam mengikuti jadwal lab apabila ada praktikum reguler penelitian dilarang masuk

Atas perhatian dan kerjasamanya, kami ucapkan terimakasih.

Catatan : Membawa bukti transfer yang sudah difotokopi dan diperbesar sebanyak 4 lembar dan Selama praktikum mahasiswa yang bersangkutan harus memakai APD lengkap ( jas praktek, masker, sepatu )

Surakarta, 26 Juni 2022  
 Ka UPT Laboratorium

Asik Gunawan

Jl.Let Jend Sutoyo, Mojosongo,Solo 57127, Telp.0271-852518, fax 0271 – 853275  
 Home page : Error! Hyperlink reference not valid. : [info @setiabudi.ac.id](mailto:info@setiabudi.ac.id)



FAKULTAS ILMU KESEHATAN

Nomor : 0396N/H6-4/4.07.2022

Lamp. : -

Hal : Pembacaan hasil penelitian

Kepada Yth. :  
Laboratorium Klinik Prima Diagnostika  
Di tempat

Dengan Hormat,

Guna memenuhi persyaratan untuk keperluan penyusunan Tugas Akhir (TA) bagi Mahasiswa Semester Akhir Program Studi D4 Analis Kesehatan Fakultas Ilmu Kesehatan Universitas Setia Budi terkait bidang yang diteliti, maka bersama ini kami mohon ijin pembacaan hasil penelitian di Laboratorium Klinik Prima Diagnostika, bagi mahasiswa kami :

1. NAMA : Vera Annisatul Ulfa  
NIM : 11180740N  
PROGDI : D4 Analis Kesehatan  
JUDUL : **"Hubungan Usia dan Indeks Massa Tubuh ( IMT) dengan Titer Antibodi Sars-Cov-2"**
2. NAMA : Erry Pramudya  
NIM : 11180748N  
PROGDI : D4 Analis Kesehatan  
JUDUL : **"Hubungan Kormobid dan Penyintas Covid-19 dengan Titer Antibodi Sars-Cov-2"**

Demikian atas bantuan dan kerjasamanya kami ucapkan terima kasih.



Surakarta, 11 Juli 2022

Jean,

Prof. dr. Marsetyawan HNE Soesatyo, M.Sc., Ph.D.

Jl. Let. Jend. Sutoyo Mojosoongo – Solo 57127, Telp. 0271 – 852518, Fax. 0271 – 853275  
Homepage : [www.setiabudi.ac.id](http://www.setiabudi.ac.id), e-mail : [usbsolo@yahoo.com](mailto:usbsolo@yahoo.com)

### Lampiran 2.Data Sampel

| No Pendaftaran | Nama Responden          | Jenis Kelamin | Usia | Komorbidity | Penyintas COVID-19 | Titer Antibodi (AU/mL) |
|----------------|-------------------------|---------------|------|-------------|--------------------|------------------------|
|                | Komorbidity as          |               |      |             |                    |                        |
| 38             | P P                     | P             | 59   | Hipertensi  | -                  | 90                     |
| 32             | A                       | P             | 43   | Hipertensi  | -                  | 92                     |
| 45             | K                       | P             | 29   | Hipertensi  | -                  | 100                    |
| 41             | T S                     | P             | 40   | Hipertensi  | -                  | 118                    |
| 11             | W                       | P             | 42   | Hipertensi  | -                  | 64                     |
| 31             | Y H                     | L             | 32   | Hipertensi  | -                  | 122                    |
| 53             | A d                     | P             | 35   | DM          | -                  | 113                    |
| 80             | M                       | P             | 42   | DM          | -                  | 110                    |
| 64             | G S                     | L             | 51   | DM          | -                  | 120                    |
| 85             | N AB                    | L             | 51   | DM          | -                  | 109                    |
|                | T                       | L             | 40   | DM          | -                  | 98                     |
|                | P                       | L             | 44   | DM          | -                  | 106                    |
|                | Tidak ada komorbidity s |               |      |             |                    |                        |
|                | Sr                      | L             | 56   | -           | -                  | 102                    |
|                | Rn                      | L             | 29   | -           | -                  | 107                    |
|                | Mk                      | L             | 50   | -           | -                  | 104                    |
|                | Nn                      | P             | 64   | -           | -                  | 124                    |
|                | Kr                      | P             | 40   | -           | -                  | 116                    |
|                | Y                       | P             | 32   | -           | -                  | 122                    |
|                | E                       | P             | 43   | -           | -                  | 126                    |
|                | In                      | P             | 33   | -           | -                  | 112                    |
|                | Pn                      | P             | 59   | -           | -                  | 115                    |
|                | Dk                      | P             | 37   | -           | -                  | 116                    |
|                | Ar                      | P             | 43   | -           | -                  | 126                    |
|                | Re                      | P             | 42   | -           | -                  | 110                    |
|                | Penyintas COVID-19      |               |      |             |                    |                        |
| 58             | C                       | P             | 41   | -           | ✓                  | 104                    |
| 56             | TSW                     | P             | 52   | -           | ✓                  | 107                    |
| 13             | D E                     | P             | 44   | -           | ✓                  | 84                     |
| 55             | Y NAP                   | P             | 30   | -           | ✓                  | 98                     |

|    |                                       |   |    |   |   |     |
|----|---------------------------------------|---|----|---|---|-----|
| 19 | W H                                   | P | 51 | - | ✓ | 110 |
|    | B                                     | L | 39 | - | ✓ | 97  |
|    | Tidak<br>penyintas<br><i>COVID-19</i> |   |    |   |   |     |
|    | Sr                                    | L | 56 | - | - | 102 |
|    | Rn                                    | L | 29 | - | - | 107 |
|    | Mk                                    | L | 50 | - | - | 104 |
|    | Nn                                    | P | 64 | - | - | 124 |
|    | Kr                                    | P | 40 | - | - | 116 |
|    | Y                                     | P | 32 | - | - | 122 |

### Lampiran 3. Dokumentasi Alat dan Bahan



Inkubator



Microplate



Elisa Reader



Reagen quantitative  
*COVID-19* IgG Elisa



Sampel serum



Elisa Washer

#### Lampiran 4. Dokumentasi Proses Penelitian



Pemisahan Serum



Penambahan reagen sampel dilution buffer



Pengambilan sampel serum



Penambahan reagen stoping solution





Reagen stoping solution warna  
biru menjadi kuning



Pemipetan reagen  
standard



Sampel dan reagen  
sampel dilution buffer



Sampel dan penambahan  
reagen stoping solution



|   | 1            | 2            | 3            | 4            | 5            | 6            |
|---|--------------|--------------|--------------|--------------|--------------|--------------|
| A | 001<br>0.751 | 009<br>0.697 | 017<br>1.274 | 025<br>1.184 | 033<br>1.625 | 041<br>1.904 |
| B | 002<br>2.394 | 010<br>1.385 | 018<br>0.749 | 026<br>2.185 | 034<br>2.019 | 042<br>1.920 |
| C | 003<br>0.968 | 011<br>0.215 | 019<br>0.458 | 027<br>1.918 | 035<br>0.162 | 043<br>2.099 |
| D | 004<br>0.768 | 012<br>1.056 | 020<br>2.040 | 028<br>1.089 | 036<br>2.273 | 044<br>1.715 |
| E | 005<br>1.878 | 013<br>1.464 | 021<br>2.167 | 029<br>1.681 | 037<br>1.711 | 045<br>2.015 |
| F | 006<br>0.835 | 014<br>1.379 | 022<br>1.578 | 030<br>2.440 | 038<br>1.970 | 046<br>1.257 |
| G | 007<br>1.433 | 015<br>1.456 | 023<br>2.195 | 031<br>2.282 | 039<br>0.946 | 047<br>0.983 |
| H | 008<br>2.040 | 016<br>2.090 | 024<br>1.230 | 032<br>1.534 | 040<br>1.551 | 048<br>2.081 |

7-12>> Send Result Print Exit

Hasil titer antibodi di  
Elisa Reader

## Lampiran 5. Prosedur Kit COVID-19 Quantitative IgG Elisa

Demeditec COVID-19 (SARS-CoV-2) quantitative IgG ELISA DECOV1901Q

### 7. SAMPLE COLLECTION AND PREPARATION

Use human serum or plasma (citrate, heparin, EDTA) samples derived from venous blood (for further sample material refer to 7.1, Additional Sample Material) with this assay. If the assay is performed within 5 days after sample collection, the samples should be kept at 2...8 °C; otherwise they should be aliquoted and stored deep-frozen (-70...-20 °C). If samples are stored frozen, mix thawed samples well before testing. Avoid repeated freezing and thawing. Heat inactivation of samples is not recommended.

#### 7.1. Additional Sample Material

Serum obtained from capillary blood e.g. from the fingertip, collected and processed using the Sarstedt Microvette® 100 Serum (product number 20.1308) device is also suitable as sample material.  
**Important:** Do not use whole blood directly with the test!

#### 7.2. Sample Dilution

Before assaying, all samples should be diluted 1+100 with **SAM DIL**. Dispense 10 µL sample and 1 mL **SAM DIL** into tubes to obtain a 1+100 dilution and thoroughly mix with a Vortex.

### 8. ASSAY PROCEDURE

Please read the instruction for use carefully **before** performing the assay. Result reliability depends on strict adherence to the instruction for use as described. The following test procedure is only validated for manual procedure. Pay attention to chapter 12. Prior to commencing the assay, a distribution and identification scheme for all samples and standards/controls (duplicates recommended) should be carefully established. Select the required number of microtiter strips or wells and insert them into the frame. Perform all assay steps in the order given and without any delays. A clean, disposable tip should be used for dispensing each standard/control and sample. Adjust the incubator to 37±1 °C.

For **quantitative** assay procedure, **CAL 1 – 5** (in duplicate), **SAM DIL**, **CONTROL 1 & 2** must be pipetted. Their target ranges are defined in the QC certificate.

For **qualitative** assay procedure, the **SAM DIL**, one standard **CAL #** (in duplicate), **CONTROL 1 & 2** must be pipetted. Their target ranges are defined in the QC certificate.

| Quantitative Assay Procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Qualitative Assay Procedure                                                                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Pipette 100 µL of the <b>SAM DIL</b> as the blank value (LW), <b>CAL 1 – 5</b> , <b>CONTROL 1 &amp; 2</b> and diluted samples into their respective wells.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 1. Pipette 100 µL of the <b>SAM DIL</b> as the blank value (LW), <b>CAL #</b> , <b>CONTROL 1 &amp; 2</b> and diluted samples into their respective wells. |
| 2. Cover wells with the foil supplied in the kit.<br>3. Incubate for 30 min at 37±1 °C.<br>4. When incubation has been completed, remove the foil, aspirate the content of the wells and wash each well four times with 300-350 µL of ready to use washing solution. The interval between washing and aspiration should be > 5 sec. At the end carefully remove remaining fluid by tapping strips on tissue paper prior to the next step!<br>Note: Washing is important! Insufficient washing results in poor precision and false results.<br>5. Dispense 100 µL <b>ENZ CONJ</b> into all wells.<br>6. Cover wells with the foil supplied in the kit.<br>7. Incubate for 30 min at 37±1 °C. Do not expose to direct sunlight.<br>8. Repeat step 4.<br>9. Dispense 100 µL of the <b>SUB TMB</b> into all wells.<br>10. Cover wells with the foil supplied in the kit.<br>11. Incubate for 30 min at 37 °C in the dark. A blue colour occurs due to an enzymatic reaction.<br>12. Dispense 50 µL <b>STOP SOLN</b> into all wells in the same order and at the same rate as for the <b>SUB TMB</b> , thereby a colour change from blue to yellow occurs. Shake plate gently and carefully until liquid is completely mixed and a uniform yellow color is visible.<br>13. Measure the absorbance at 450/620 nm (reference wavelength 620-690 nm) within 1 h after addition of the <b>STOP SOLN</b> . |                                                                                                                                                           |

#### 8.1. Measurement

Measure the absorbance of all wells at 450 nm.

Bichromatic measurement using a reference wavelength of 620-690 nm is recommended.

Where applicable calculate the mean absorbance values of all duplicates.

Version 01-2021-02-11/DLB

Updated 210224

6

Feb. 21

DLB

## QC certificate



Demeditec Diagnostics GmbH  
Lise-Meitner-Straße 2  
24145 Kiel, Germany  
Phone: +49 (0)431-71922-0  
Fax: +49 (0)431-71922-55  
info@demeditec.de  
www.demeditec.de

## COVID-19 (SARS-CoV-2) quantitative IgG ELISA

Kat.-Nr./ Cat.-No.: DECOV1901Q

|           | Lot      | Exp.date   |
|-----------|----------|------------|
| Lot       | CVGQ-002 | 2023-03-08 |
| SORB MT   | 101      | 2023-03-08 |
| CAL 1     | 10111    | 2023-03-08 |
| CAL 2     | 10111    | 2023-03-08 |
| CAL 3     | 10111    | 2023-03-08 |
| CAL 4     | 10111    | 2023-03-08 |
| CAL 5     | 10111    | 2023-03-08 |
| CONTROL 1 | 10111    | 2023-03-08 |
| CONTROL 2 | 10111    | 2023-03-08 |
| ENZ CONJ  | 10121    | 2023-03-08 |
| STOP SOLN | 01261    | 2023-03-08 |
| SUB TMB   | 01331    | 2023-03-08 |
| WASH SOLN | 01251    | 2023-03-08 |
| SAM DIL   | 01421    | 2023-03-08 |

|       | Concentration<br>AU/ml | WHO Standard<br>calibrated concentration<br>IU/ml | OD    | OD<br>Validation Criteria |
|-------|------------------------|---------------------------------------------------|-------|---------------------------|
| CAL 1 | 185                    | 666                                               | 1.781 | > 1.000 and > CAL 2       |
| CAL 2 | 92                     | 331                                               | 1.336 | > CAL 3                   |
| CAL 3 | 46                     | 166                                               | 0.884 | > CAL 4                   |
| CAL 4 | 23                     | 83                                                | 0.504 | > CAL 5                   |
| CAL 5 | 12                     | 43                                                | 0.252 | > LW                      |

|              | OD    | Value found<br>AU/ml | Target Range<br>AU/ml |
|--------------|-------|----------------------|-----------------------|
| CONTROL 2    | 0.010 | 0.18                 | 0 - 10                |
| CONTROL 1    | 1.123 | 66                   | 48.07 - 126.73        |
| OD LW < 0.15 |       |                      |                       |

## Qualitative data analysis

|               | Correction Factor (CF) |
|---------------|------------------------|
| CAL 4 = CAL # | 0.58                   |

|                         | OD    | Target Value<br>AU | Target Range<br>AU |
|-------------------------|-------|--------------------|--------------------|
| OD Cut-off = CAL # x CF | 0.29  | 10                 | -                  |
| CONTROL 2               | 0.010 | 0.75               | 0 - 5              |
| CONTROL 1               | 1.123 | 55.2               | 30.36 - 80.40      |
| OD LW < 0.15            |       |                    |                    |

Datum/Date: 17-02-2021

Überprüft/validated:

## Lampiran 6. Hasil Uji Variabel Komorbiditas

### 1. Uji Normalitas

**Case Processing Summary**

|                | Komorbiditas | Cases |         |         |         |       |         |
|----------------|--------------|-------|---------|---------|---------|-------|---------|
|                |              | Valid |         | Missing |         | Total |         |
|                |              | N     | Percent | N       | Percent | N     | Percent |
| Titer Antibodi | Hipertensi   | 6     | 100.0%  | 0       | 0.0%    | 6     | 100.0%  |
|                | DM           | 6     | 100.0%  | 0       | 0.0%    | 6     | 100.0%  |

**Tests of Normality**

|                | Komorbiditas | Kolmogorov-Smirnov <sup>a</sup> |    |       | Shapiro-Wilk |    |      |
|----------------|--------------|---------------------------------|----|-------|--------------|----|------|
|                |              | Statistic                       | df | Sig.  | Statistic    | df | Sig. |
| Titer Antibodi | Hipertensi   | .192                            | 6  | .200* | .941         | 6  | .666 |
|                | DM           | .158                            | 6  | .200* | .982         | 6  | .959 |

\*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

## Descriptives

|                | Komorbiditas |                                  | Statistic             | Std. Error |
|----------------|--------------|----------------------------------|-----------------------|------------|
| Titer Antibodi | Hipertensi   | Mean                             | 97.67                 | 8.632      |
|                |              | 95% Confidence Interval for Mean | Lower Bound<br>75.48  |            |
|                |              |                                  | Upper Bound<br>119.86 |            |
|                |              | 5% Trimmed Mean                  | 98.19                 |            |
|                |              | Median                           | 96.00                 |            |
|                |              | Variance                         | 447.067               |            |
|                |              | Std. Deviation                   | 21.144                |            |
|                |              | Minimum                          | 64                    |            |
|                |              | Maximum                          | 122                   |            |
|                |              | Range                            | 58                    |            |
|                |              | Interquartile Range              | 36                    |            |
|                |              | Skewness                         | -.507                 | .845       |
|                |              | Kurtosis                         | .092                  | 1.741      |
|                | DM           | Mean                             | 109.33                | 2.985      |
|                |              | 95% Confidence Interval for Mean | Lower Bound<br>101.66 |            |
|                |              |                                  | Upper Bound<br>117.01 |            |
|                |              | 5% Trimmed Mean                  | 109.37                |            |
|                |              | Median                           | 109.50                |            |
|                |              | Variance                         | 53.467                |            |
|                |              | Std. Deviation                   | 7.312                 |            |
|                |              | Minimum                          | 98                    |            |
|                |              | Maximum                          | 120                   |            |
|                |              | Range                            | 22                    |            |
|                |              | Interquartile Range              | 11                    |            |
|                |              | Skewness                         | -.176                 | .845       |
|                |              | Kurtosis                         | 1.034                 | 1.741      |



## 2. Uji Independen Sampe T Test

|                                |                            | Independent Samples Test |       |        |    |                 |
|--------------------------------|----------------------------|--------------------------|-------|--------|----|-----------------|
|                                |                            | F                        | Sig.  | t      | df | Sig. (2-tailed) |
| <b>Faktor<br/>Komorbiditas</b> | Equal variances<br>assumed | 3,073                    | 0,094 | -2,180 | 22 | 0,040           |

## Lampiran 7. Hasil Uji Variabel Penyintas COVID-19

### 1. Uji Normalitas

**Case Processing Summary**

|                |                           | Cases |         |         |         |       |         |
|----------------|---------------------------|-------|---------|---------|---------|-------|---------|
|                |                           | Valid |         | Missing |         | Total |         |
|                |                           | N     | Percent | N       | Percent | N     | Percent |
| Titer Antibodi | Penyintas                 | 6     | 100.0%  | 0       | 0.0%    | 6     | 100.0%  |
|                | Komorbidity dan penyintas | 6     | 100.0%  | 0       | 0.0%    | 6     | 100.0%  |

**Tests of Normality**

|                |                           | Kolmogorov-Smirnov <sup>a</sup> |    |       | Shapiro-Wilk |    |      |
|----------------|---------------------------|---------------------------------|----|-------|--------------|----|------|
|                |                           | Statistic                       | df | Sig.  | Statistic    | df | Sig. |
| Titer Antibodi | Penyintas                 | .207                            | 6  | .200* | .927         | 6  | .554 |
|                | Komorbidity dan penyintas | .226                            | 6  | .200* | .914         | 6  | .463 |

\*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction



## Descriptives

|                | Penyintas                  |                                  | Statistic                                     | Std. Error |
|----------------|----------------------------|----------------------------------|-----------------------------------------------|------------|
| Titer Antibodi | Penyintas                  | Mean                             | 100.00                                        | 3.804      |
|                |                            | 95% Confidence Interval for Mean | Lower Bound<br>90.22<br>Upper Bound<br>109.78 |            |
|                |                            | 5% Trimmed Mean                  | 100.33                                        |            |
|                |                            | Median                           | 101.00                                        |            |
|                |                            | Variance                         | 86.800                                        |            |
|                |                            | Std. Deviation                   | 9.317                                         |            |
|                |                            | Minimum                          | 84                                            |            |
|                |                            | Maximum                          | 110                                           |            |
|                |                            | Range                            | 26                                            |            |
|                |                            | Interquartile Range              | 14                                            |            |
|                |                            | Skewness                         | -1.011                                        | .845       |
|                |                            | Kurtosis                         | 1.024                                         | 1.741      |
|                | Komorbiditas dan penyintas | Mean                             | 96.17                                         | 7.364      |
|                |                            | 95% Confidence Interval for Mean | Lower Bound<br>77.24<br>Upper Bound<br>115.10 |            |
|                |                            | 5% Trimmed Mean                  | 96.46                                         |            |
|                |                            | Median                           | 97.00                                         |            |
|                |                            | Variance                         | 325.367                                       |            |
|                |                            | Std. Deviation                   | 18.038                                        |            |
|                |                            | Minimum                          | 71                                            |            |
|                |                            | Maximum                          | 116                                           |            |
|                |                            | Range                            | 45                                            |            |
|                |                            | Interquartile Range              | 32                                            |            |
|                |                            | Skewness                         | -.280                                         | .845       |
|                |                            | Kurtosis                         | -1.876                                        | 1.741      |

## 2. Uji Independen Sample T Test

|                                          |                            | Independent Samples Test |       |        |    |                 |
|------------------------------------------|----------------------------|--------------------------|-------|--------|----|-----------------|
|                                          |                            | F                        | Sig.  | t      | df | Sig. (2-tailed) |
| <b>Faktor<br/>Penyintas<br/>COVID-19</b> | Equal variances<br>assumed | 0,218                    | 0,651 | -2,306 | 10 | 0,044           |



## KUISIONER

Judul Skripsi : HUBUNGAN KOMORBIDITAS DAN PENYINTAS COVID-19 DENGAN  
TITER ANTIBODI SARS-COV-2 PENDUDUK KELURAHAN  
MOJOSONGO JEBRES SURAKARTA

1. Nama : Peni
2. Umur : 59 th
3. Jenis Kelamin : Perempuan
4. Alamat : Jl. Merbabu No. 27
5. Apakah anda sudah mendapatkan vaksinasi ?
  - ☐ Vaksin 1
  - ☐ Vaksin 2
  - ☒ Vaksin 3 ( booster )
  - ☐ Belum vaksinasi
6. Berapa lama anda sudah mendapatkan vaksinasi ?
  - ☒ 1 – 3 bulan
  - ☐ 3 – 6 bulan
  - ☐ 6 – 9 bulan
  - ☐ > 9 bulan
7. Penyintas Covid-19 adalah seseorang yang pernah terkonfirmasi positif Covid-19 hingga dinyatakan sembuh.  
Apakah anda termasuk dalam Penyintas Covid-19 ?
  - ☐ Iya, termasuk
  - ☒ Tidak termasuk

Jl. Let. Jend. Gutoyo Mojosongo – Solo 57127, Telp. 0271 – 852518, Fax. 0271 – 853276  
Homepage : [www.setiabudi.ac.id](http://www.setiabudi.ac.id), e-mail : [usb.solo@yahoo.com](mailto:usb.solo@yahoo.com)



Komorbid adalah merupakan penyakit penyerta ( penyakit lain yang dialami pasien) selain penyakit utama (Covid-19), seperti :

8. Hipertensi adalah pasien dengan kondisi tekanan darah yang tinggi ( > 130/80 mmHg) dengan gejala klinis : sakit kepala / pusing, mudah lelah, jantung berdebar-debar, rasa sakit di dada, gelisah, penglihatan kabur.  
Apakah anda termasuk memiliki hipertensi ?
  - ☒ Iya, termasuk
  - ☐ Tidak termasuk
9. Diabetes Mellitus adalah penyakit kronis yang ditandai dengan meningkatnya kadar gula dalam darah (glukosa darah tinggi) dengan gejala klinis : meningkatnya frekuensi buang air kecil, rasa haus berlebihan, sering merasa lapar, luka yang sulit sembuh.  
Apakah anda termasuk memiliki Diabetes Mellitus ?
  - ☐ Iya, termasuk
  - ☒ Tidak termasuk
10. Penyakit paru kronik adalah aliran udara dari paru-paru terhalang oleh pembengkakan dan lendir / dahak yang biasanya disebut sesak napas. Dengan gejala klinis : sesak napas, batuk terus menerus (selama 2 minggu) dan berdahak.  
Apakah anda termasuk memiliki Penyakit paru kronik ?
  - ☐ Iya, termasuk
  - ☒ Tidak termasuk
11. Penyakit kardiovaskular adalah adanya gangguan pada fungsi jantung dan pembuluh darah / yang biasa disebut dengan penyakit jantung dan stroke. Dengan gejala klinis : sesak napas, pusing / mual, lemas hingga penurunan kesadaran, nyeri di dada dan jantung berdebar (lebih cepat).  
Apakah anda termasuk dalam penyakit kardiovaskular ?
  - ☐ Iya, termasuk
  - ☒ Tidak termasuk

## Lampiran 9. Form Inform Consent



### PERMOHONAN MENJADI RESPONDEN

Kepada Yth.  
Calon responden penelitian  
Di tempat

Dengan hormat,  
Saya yang bertandatangan di bawah ini :  
Nama : Erry Pramudya  
NIM : 11180748N  
Pendidikan : Program studi D4 Analis Kesehatan

Saya mahasiswa Universitas Setia Budi Surakarta sedang melakukan penelitian dengan judul *"Hubungan Faktor Komorbiditas Dan Penyintas COVID-19 Dengan Titer Antibodi SARS-COV-2 Penduduk Kelurahan Mojosoongo Jebres Surakarta"*. Penelitian ini tidak menimbulkan kerugian bagi saudara yang menjadi responden. Kerahasiaan informasi yang diberikan akan dijaga dan akan diperlukan hanya untuk kepentingan penelitian saja. Jika saudara menyetujui maka saya mohon kesediaannya untuk menandatangani lembar persetujuan menjadi responden. Atas ketersediaannya saya ucapkan terima kasih.

Hormat saya

Erry Pramudya

Jl. Let. Jend. Sutoyo Mojosoongo – Solo 57127, Telp. 0271 – 852518, Fax. 0271 – 853275  
Homepage [www.setiabudi.ac.id](http://www.setiabudi.ac.id), e-mail : [usbsolo@yahoo.com](mailto:usbsolo@yahoo.com)



### LEMBAR PERSETUJUAN MENJADI RESPONDEN

Saya yang bertandatangan dibawah ini, bersedia menjadi perwakilan responden penelitian atas pengambilan sampel serum yang dilakukan oleh mahasiswa program studi D4 Analisis Kesehatan Universitas Setia Budi Surakarta yang bernama Erry Pramudya dengan judul *"Hubungan Faktor Komorbiditas Dan Penyintas COVID-19 Dengan Titer Antibodi SARS-COV-2 Penduduk Kelurahan Mojosoongo Jebres Surakarta"*.

Saya memahami bahwa hasil yang diperoleh bersifat rahasia dan hanya digunakan sebagai kepentingan penelitian dan pengembangan ilmu pengetahuan. Penelitian ini tidak merugikan saya, oleh karena itu saya bersedia menjadi responden dan akan memberikan pernyataan dan informasi yang sebenar-benarnya tanpa tekanan dimanapun.

Surakarta, 24 Juni 2022

Responden

  
(.....Pen.....)

Jl. Let. Jend. Sutoyo Mojosoongo – Solo 57127, Telp. 0271 – 852518, Fax. 0271 – 853275  
Homepage [www.setiabudi.ac.id](http://www.setiabudi.ac.id), e-mail : [ustsolo@yahoo.com](mailto:ustsolo@yahoo.com)